Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Dietary Management

- PMLiVE

EC launches cancer imaging initiative to accelerate innovation and early diagnosis

Researchers will have better access to high-quality resources and databases

- PMLiVE

Digital technology: a significant change in healthcare innovation

By Megan Allen

- PMLiVE

Neurodiversity and healthcare communications – do we know enough and do we do enough?

By Robert Goodwin

Virtual Steering Committee & Peer Influence Program

In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program.

Impetus Digital

- PMLiVE

Alzheimer’s Society urges UK government to deliver on dementia plan

The strategy, announced in May last year, includes doubling dementia research funding

- PMLiVE

Ipsen reports positive phase 3 data for Onivyde in pancreatic cancer

The investigational treatment regimen met its primary endpoint of overall survival

- PMLiVE

BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia

The BTK inhibitor demonstrated better results than Imbruvica, a standard of care treatment in CLL

- PMLiVE

Meeting healthcare’s rising challenges

The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential

- PMLiVE

Omnichannel communications in Medical Affairs: closing the gap between aspiration and reality

By Stephen Jones, Heather Bennett and Agustin Ramirez

- PMLiVE

SCIRIS ACQUIRES SOURCE HEALTH ECONOMICS

Global healthcare communications company SCIRIS is delighted to announce the acquisition of UK-based Source Health Economics – an agency specialising in health economics and outcomes research (HEOR).The development is the...

Porterhouse Medical Group

- PMLiVE

Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval

The FDA said there was not enough trial data from patients who were treated for at least a year

- PMLiVE

BeiGene’s Brukinsa granted two new marketing authorisations by MHRA

The BTK inhibitor is now approved for chronic lymphocytic leukaemia and marginal zone lymphoma

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links